Clinical trials
ctDNA clinical trials
Below are recruiting ctdna clinical trials, each written for real people, not researchers. We’re tracking 186 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04616131Recruiting
Testing ctDNA as a marker in pancreatic cancer treatment
This trial is studying a blood test that looks for tumor DNA (ctDNA) to see if it can help predict how well treatment is working in people with pancreatic cancer that hasn't spread. It is for patients getting chemotherapy before possible surgery.
DeKalb, IllinoisAges 18 years+ - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT04846933Recruiting
Testing extra scans and data to guide ovarian cancer treatment
This trial collects information from people with suspected ovarian cancer and uses it to improve diagnosis and help predict which treatments may work. It may also look for targeted options, based on scan and medical data results.
TurkuAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT04931732Recruiting
Liquid blood test to diagnose brain glioma
This trial checks whether a special blood test can help identify glioma (a type of brain tumor) that is new or coming back. It may help doctors learn more about the tumor using blood, alongside the usual brain scans and planned surgery.
BronAges 18–90 - NCT07366112RecruitingPhase 2
CDK4/6 inhibitor plus hormone therapy before breast cancer surgery
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT04957901Recruiting
Tracking a blood marker in children with lymphoma
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
GuangzhouAges 1–18 - NCT05052671Recruiting
Blood test for residual cancer in resectable pancreatic cancer
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Oklahoma City, OklahomaAges 18–99 - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05081024Recruiting
Blood test biomarker to help preserve organs in rectal cancer
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Portland, OregonAges 18 years+ - NCT05234177Recruiting
Blood test to track colorectal cancer after surgery
This study looks at a blood “DNA” test to see if it can help monitor colorectal cancer after surgery. It may benefit you by improving how doctors track cancer during routine follow-up visits.
Fort Smith, ArkansasAges 18 years+ - NCT05254782Recruiting
Blood test after lung tumor surgery to find hidden disease
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Toronto, OntarioAges 18 years+ - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT05343013RecruitingPhase 2
TAS-102 with or without celecoxib for leftover colon cancer DNA
This Phase 2 study tests TAS-102, with or without celecoxib, to treat “minimal residual disease” (tiny traces of colon cancer) found in a blood test after standard chemotherapy. The goal is to reduce the chance that colon cancer returns after treatment.
Houston, TexasAges 18 years+ - NCT05366816RecruitingPhase 2
Blood test–guided sunitinib or regorafenib for GIST
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
Miami, FloridaAges 18 years+ - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05529615Recruiting
Blood DNA test guides chemotherapy after colon cancer surgery
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
Beijing, Beijing MunicipalityAges 18–75 - NCT05536089Recruiting
Testing blood methylation to predict colorectal cancer relapse
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
Hangzhou, ZhejiangAges 18 years+ - NCT05572801Recruiting
Tumor DNA blood tests to guide follow-up after anal cancer
This study tests whether regular blood tests looking for “tumor DNA” can help guide your follow-up care after anal cancer treatment. It may help doctors decide what type of monitoring you need during check-ups.
Herlev, Capital Region of DenmarkAges 18 years+ - NCT05658172Recruiting
Less vs more frequent follow-up after early breast cancer
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
UlmAges 18–75
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ctdna?
- Yes. Clin2 currently lists 186 recruiting ctdna studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ctdna trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ctdna trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.